Journal
INTERNAL MEDICINE JOURNAL
Volume 48, Issue 6, Pages 637-644Publisher
WILEY
DOI: 10.1111/imj.13810
Keywords
pancreatic cancer; adenocarcinoma; metastatic; cytotoxic chemotherapy; clinical trials; cancer genomics
Categories
Ask authors/readers for more resources
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available